ArticleCancer medicine2023

Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.

Jon Apple et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.